AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications
By Elana Gotkine HealthDay Reporter
TUESDAY, March 11, 2025 -- Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 10 to 14 in San Diego.
Shivan N. Chokshi, M.D., from the University of Tennessee Campbell Clinic in Memphis, and colleagues examined the association between the time of last Ozempic dose and anesthesia complications in patients who underwent total hip or knee arthroplasty from January 2018 to January 2023. Ozempic users were classified based on when they stopped medication before surgery (482, 591, 680, 758, 777, and 706 at 30, 14, seven, five, three, and one day before surgery, respectively; 170 patients continued use through surgery); the control group included 206,005 patients without prior Ozempic use.
The researchers found that stopping Ozempic five days, three days, and one day prior to surgery was an independent risk factor for delayed emergence from anesthesia (odds ratios, 1.59, 1.84, and 2.23, respectively). Stopping seven days prior was a risk factor for aspiration pneumonitis (odds ratio, 1.29), with higher risks seen for stopping five days and one day prior (odds ratios, 2.74 and 2.74, respectively). Last Ozempic dose at seven days prior to surgery was identified as an independent risk factor for conversion to intubation in multivariate logistic regression (odds ratio, 1.39). Last Ozempic dose at five days, three days, and one day prior were independent risk factors for conversion to intubation (odds ratios, 2.09, 4.68, and 6.37, respectively). Patients who continued Ozempic through surgery had the highest risk for complications.
"To minimize risks of delayed emergence from anesthesia, aspiration, aspiration pneumonitis, and conversion to intubation, ceasing GLP-1 RA 14 days before surgery is optimal," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Pediatric Magnet Ingestion Rates Still High
THURSDAY, May 22, 2025 -- Global pediatric magnet ingestion rates remain high and incidence has increased, despite the implementation of national policies, according to a review...
Similar Survival Seen With Simple Versus Radical Hysterectomy for Cervical Cancer
WEDNESDAY, May 21, 2025 -- For patients with low-risk cervical cancer, survival is similar following simple hysterectomy (SH) versus modified radical hysterectomy (MRH) or radical...
Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy
TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.